AJ Lanigan: Sure. Actually, Pharma firms are earning major income with therapies like Keytruda and Opdivo that deal with PD-one and PD-L1. Right here’s the super cool section: consider checkpoints as traffic signals. You don’t want an immune program that’s running wild just like a freight educate about a cliff. waiting for link from Social Bookmarking (4)